Even though the final implementation date for ICD-10 has yet to be determined, the Centers for Medicare & Medicaid Services (CMS) now is offering responses to top questions about the Version 5010/4010A electronic standards upgrade.

The American Society of Clinical Oncology (ACSO) has identified the top five opportunities to improve care and reduce costs in oncology. PET, CT and radionuclide bone scanning dominate the list of high-cost, low-yield strategies and should be avoided in specific clinical scenarios, according to ASCO. The list was detailed online April 3 in the Journal of Clinical Oncology.

AG Mednet has released a Submission Quality & Compliance module that delivers quality assurance software to support organizations in the clinical trial ecosystem, including imaging core labs, clinical research organizations, imaging trial sponsors and principal investigators.

In April, employment rose in the healthcare sector by 19,000, according to the U.S. Bureau of Labor Statistics.

Medtronic has announced that the Resolute Integrity coronary drug-eluting stent (DES) system has received European regulatory approval for several new indications.

The high-risk variant, ApoE4, triggers an inflammatory reaction that weakens the blood-brain barrier, a network of cells and other components that lines brain vessels, which would normally create a barrier to nutrients into the brain and keep harmful substances out, according to a study published May 16 in Nature. Researchers have found that in mice, having the most risky variant of ApoE damages the blood vessels that feed the brain.

Postmortem cardiac CT angiography (CTA) and image-guided biopsy have the potential to aid in defining the cause of death after acute chest pain. In addition to being a minimally invasive method of supplying information comparable to that provided by traditional autopsy, these imaging modalities expose additional histopathologic information that could further substantiate a final diagnosis, according to a study published online May 8 in Radiology.

Jefferson's Kimmel Cancer Center and the department of radiology at Thomas Jefferson University in Philadelphia received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a method that may stage prostate cancers and detect recurrent disease, potentially reducing the number of confirmation biopsies. The technique involves the use of a PET scan and a novel imaging agent.